Latest Breaking News On - டிரில்லியம் சிகிச்சை - Page 8 : comparemela.com
Form 6-K Profound Medical Corp For: May 19
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
eQcell Inc Announces the Appointment of Members of the Board of Directors
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer
FinancialBuzz.com News Commentary
NEW YORK, April 9, 2021 /PRNewswire/ The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in the United States in 2020. Overall, lung and bronchus cancer is the second most common cancer diagnosis with an estimated 228,820 new cases. Prostate cancer is the leading cancer diagnosis among men and the third most common diagnosis overall with 191,930 expected cases. However, the increase in competition and continuous technological advancements has led to improvements in the product portfolios of biotech firms in the field. Therefore, product approvals and product development are one of the key developmental strategies adopted by market players in the global cancer therapeutics market. And, according to a report by Mordor Intelligence, the breast c
We re #34! Pot stocks, energy sector lead TSX in Q1
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Entheon Biomedical Corp.: Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer.
Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of strategic relationships with third parties, including regulatory authorities. Importantly, Dr. Jahns will also work to develop a commercialization and post-market strategy for Entheon s therapeutic protocols, while developing and advancing other related products, services, and initiatives of the company.